e-learning
resources
ERJ
2016
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Imaging and molecular biomarkers: a novel approach to screen populations at risk of pulmonary fibrosis?
Ivan O. Rosas
Source:
Eur Respir J 2016; 48: 1271-1273
Journal Issue:
November
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Ivan O. Rosas. Imaging and molecular biomarkers: a novel approach to screen populations at risk of pulmonary fibrosis?. Eur Respir J 2016; 48: 1271-1273
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
N
-ethyl-
N
-nitrosourea mutagenesis: a new tool for exploring lung disease
Source: Annual Congress 2010 - Scientific Year in Review
Year: 2010
Novel strategy to identify genetic risk factors for COPD severity: a genetic isolate
Source: Eur Respir J 2010; 35: 768-775
Year: 2010
Genetic studies as a tool for identifying novel potential targets for treatment of COPD
Source: Eur Respir J, 50 (5) 1702042; 10.1183/13993003.02042-2017
Year: 2017
Evaluation of recently validated non-invasive formula using basic lung functions as a new screening tool for pulmonary hypertension in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2009 - Pulmonary vascular diseases
Year: 2009
Validation of a novel prognostic tool for idiopathic pulmonary fibrosis
Source: Annual Congress 2012 - Diffuse parenchymal lung disease I
Year: 2012
Molecular endpoints for establishing target engagement by novel idiopathic pulmonary fibrosis therapies
Source: Eur Respir J, 53 (3) 1900283; 10.1183/13993003.00283-2019
Year: 2019
Distance assessment of the risk of pulmonary hypertension associated with connective tissue diseases: do biomarkers help?
Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond
Year: 2021
Fibrocytes: potential new therapeutic targets for pulmonary hypertension?
Source: Eur Respir J 2010; 36: 1232-1235
Year: 2010
Proteomic analysis of sputum from adults with cystic fibrosis and COPD: identification of potential biomarkers for disease monitoring
Source: Eur Respir J 2006; 28: Suppl. 50, 152s
Year: 2006
Novel strategy to identify genetic risk factors for COPD severity: genetically isolated populations
Source: Annual Congress 2008 - Genetic risk factors for asthma and COPD
Year: 2008
Novel imaging biomarkers for assessment of lung fibrosis and inflammation
Source: Virtual Congress 2021 – Emerging imaging biomarkers in lung disease
Year: 2021
PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery
Source: Eur Respir Rev 2013; 22: 148-152
Year: 2013
Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies?
Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021
Year: 2022
Proof of concept of a non-invasive screening tool to detect idiopathic pulmonary fibrosis (IPF) in an early stage
Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias?
Year: 2018
COPD – will new insights into molecular pathology define new therapies?
Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD
Year: 2014
Risk stratification of pulmonary embolism: clinical evaluation, biomarkers or both?
Source: Eur Respir J 2015; 46: 1551-1553
Year: 2015
Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort
Source: Eur Respir J, 57 (6) 2002591; 10.1183/13993003.02591-2020
Year: 2021
Gene expression profiles of idiopathic interstitial pneumonias: Identification of disease-specific diagnostic markers and molecular therapeutic targets
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept